Vaccines, Biosimilars In Shadow As Sun Shines On Ranbaxy?
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma may eliminate biosimilars and vaccines work that was being done by Ranbaxy at its two units in Hyderabad and Bangalore. The move could symbolize the thinking of Sun management – to stay away from venturing into product segments that are highly competitive or still evolving.
You may also be interested in...
Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.